|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Sage Therapeutics, Inc. (SAGE) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
58,290,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Sage Therapeutics is a biopharmaceutical company focused on developing and commercializing medicines with the potential to transform the lives of people with debilitating disorders of the brain. Co.'s principal product, ZULRESSO, is a proprietary intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. Co.'s other product candidate is zuranolone (SAGE-217), an oral compound being developed for certain affective disorders, including major depressive disorder, and PPD. Co. has a portfolio of other compounds that target GABAA receptors, including SAGE-324. SAGE-324 is a GABAA receptor positive allosteric modulator intended for chronic oral dosing.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
3,000 |
25,500 |
| Total Buy Value |
$0 |
$0 |
$87,779 |
$839,364 |
| Total People Bought |
0 |
0 |
1 |
3 |
| Total Buy Transactions |
0 |
0 |
2 |
4 |
| Total Shares Sold |
0 |
0 |
0 |
11,643 |
| Total Sell Value |
$0 |
$0 |
$0 |
$519,413 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Paul Steven M |
|
– • – |
2015-08-03 |
4 |
AS |
$66.42 |
$1,341,692 |
D/D |
(20,000) |
703,650 |
|
- |
|
| Kanes Stephen |
Chief Medical Officer |
• – – |
2015-07-27 |
4 |
AS |
$68.50 |
$346,723 |
D/D |
(4,936) |
43,948 |
|
- |
|
| Kanes Stephen |
Chief Medical Officer |
• – – |
2015-07-27 |
4 |
OE |
$0.45 |
$871 |
D/D |
1,936 |
48,884 |
|
- |
|
| Jonas Jeffrey M |
See Remarks |
• • – |
2015-07-23 |
4 |
AS |
$76.79 |
$230,370 |
D/D |
(3,000) |
81,000 |
|
- |
|
| Iguchi Kimi |
CFO, Secretary and Treasurer |
• – – |
2015-07-06 |
4 |
AS |
$68.00 |
$272,000 |
D/D |
(4,000) |
91,563 |
|
- |
|
| Paul Steven M |
|
– • – |
2015-07-01 |
4 |
AS |
$67.46 |
$1,388,028 |
D/D |
(20,000) |
723,650 |
|
- |
|
| Robichaud Albert |
Chief Scientific Officer |
• – – |
2015-07-01 |
4 |
AS |
$70.62 |
$1,154,157 |
D/D |
(16,000) |
194,222 |
|
- |
|
| Kanes Stephen |
Chief Medical Officer |
• – – |
2015-06-24 |
4 |
AS |
$74.06 |
$444,360 |
D/D |
(6,000) |
46,948 |
|
- |
|
| Kanes Stephen |
Chief Medical Officer |
• – – |
2015-06-24 |
4 |
OE |
$0.45 |
$2,700 |
D/D |
6,000 |
52,948 |
|
- |
|
| Starr Kevin P |
Director |
– • • |
2015-06-19 |
4 |
A |
$0.00 |
$0 |
D/D |
9,403 |
27,331 |
|
- |
|
| Starr Kevin P |
Director |
– • • |
2015-06-19 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,064,607) |
0 |
|
- |
|
| Starr Kevin P |
Director |
– • • |
2015-06-19 |
4 |
A |
$0.00 |
$0 |
I/I |
64,607 |
64,607 |
|
- |
|
| Tepper Robert I |
10% Owner |
– – • |
2015-06-19 |
4 |
A |
$0.00 |
$0 |
D/D |
83,412 |
27,331 |
|
- |
|
| Tepper Robert I |
10% Owner |
– – • |
2015-06-19 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,064,607) |
0 |
|
- |
|
| Nelsen Robert |
Director |
– • • |
2015-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
53,992 |
60,127 |
|
- |
|
| Nelsen Robert |
Director |
– • • |
2015-06-18 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,062,345) |
2,124,699 |
|
- |
|
| Bybee Clinton |
10% Owner |
– – • |
2015-06-18 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,062,345) |
2,124,699 |
|
- |
|
| Jonas Jeffrey M |
See Remarks |
• • – |
2015-06-16 |
4 |
OE |
$0.45 |
$72,216 |
D/D |
160,481 |
84,000 |
|
- |
|
| Jonas Jeffrey M |
See Remarks |
• • – |
2015-06-16 |
4 |
AS |
$75.51 |
$8,775,137 |
D/D |
(115,226) |
6,000 |
|
- |
|
| Jonas Jeffrey M |
See Remarks |
• • – |
2015-06-15 |
4 |
OE |
$0.45 |
$52,254 |
D/D |
116,119 |
38,745 |
|
- |
|
| Jonas Jeffrey M |
See Remarks |
• • – |
2015-06-15 |
4 |
AS |
$78.22 |
$6,589,283 |
D/D |
(83,374) |
6,000 |
|
- |
|
| Anderson Thomas |
See Remarks |
• – – |
2015-06-08 |
4 |
AS |
$78.56 |
$438,057 |
D/D |
(5,500) |
6,000 |
|
- |
|
| Anderson Thomas |
See Remarks |
• – – |
2015-06-08 |
4 |
OE |
$8.92 |
$49,060 |
D/D |
5,500 |
11,500 |
|
- |
|
| Iguchi Kimi |
See Remarks |
• – – |
2015-06-08 |
4 |
AS |
$80.10 |
$200,250 |
D/D |
(2,500) |
95,563 |
|
- |
|
| Robichaud Albert |
Chief Scientific Officer |
• – – |
2015-06-01 |
4 |
AS |
$71.21 |
$1,164,735 |
D/D |
(16,000) |
210,222 |
|
- |
|
261 Records found
|
|
Page 9 of 11 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
